March 14, 2018 / 8:26 PM / 6 months ago

BRIEF-Miragen Therapeutics Reports Qtrly ‍loss Per Share $0.29​

March 14 (Reuters) - Miragen Therapeutics Inc:

* MIRAGEN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* MIRAGEN THERAPEUTICS INC QTRLY ‍LOSS PER SHARE $0.29​

* MIRAGEN THERAPEUTICS INC - ‍INTENDS TO INITIATE A PHASE 2 CLINICAL TRIAL FOR COBOMARSEN IN PATIENTS WITH CTCL IN SECOND HALF OF 2018​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below